These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 19625495

  • 1. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
    Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, Chang JK, Ampil F, Glass J, Nathan CO.
    Mol Cancer Ther; 2009 Aug; 8(8):2255-65. PubMed ID: 19625495
    [Abstract] [Full Text] [Related]

  • 2. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F, Weichert W, Stenzinger A, Budach V, Tinhofer I.
    J Transl Med; 2015 Apr 01; 13():106. PubMed ID: 25890004
    [Abstract] [Full Text] [Related]

  • 3. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
    Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, Glass J, Agarwal A, Caldito G.
    Cancer Res; 2007 Mar 01; 67(5):2160-8. PubMed ID: 17332346
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH.
    Neoplasia; 2013 Jun 01; 15(6):620-30. PubMed ID: 23730210
    [Abstract] [Full Text] [Related]

  • 7. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.
    Cancer Res; 2005 Nov 01; 65(21):9953-61. PubMed ID: 16267020
    [Abstract] [Full Text] [Related]

  • 8. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
    Bozec A, Ebran N, Radosevic-Robin N, Sudaka A, Monteverde M, Toussan N, Etienne-Grimaldi MC, Nigro CL, Merlano M, Penault-Llorca F, Milano G.
    Laryngoscope; 2016 Apr 01; 126(4):E156-63. PubMed ID: 26597440
    [Abstract] [Full Text] [Related]

  • 9. Retinoblastoma RB94 enhances radiation treatment of head and neck squamous cell carcinoma.
    Araki K, Ahmad SM, Li G, Bray DA, Saito K, Wang D, Wirtz U, Sreedharan S, O'Malley BW, Li D.
    Clin Cancer Res; 2008 Jun 01; 14(11):3514-9. PubMed ID: 18519784
    [Abstract] [Full Text] [Related]

  • 10. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.
    McNally LR, Rosenthal EL, Zhang W, Buchsbaum DJ.
    Cancer Gene Ther; 2009 Mar 01; 16(3):246-55. PubMed ID: 18846112
    [Abstract] [Full Text] [Related]

  • 11. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
    Schnoell J, Stanisz I, Jank BJ, Stanek V, Schmid R, Brunner M, Heiduschka G, Kotowski U.
    Invest New Drugs; 2022 Apr 01; 40(2):224-231. PubMed ID: 34613571
    [Abstract] [Full Text] [Related]

  • 12. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.
    Clémenson C, Jouannot E, Merino-Trigo A, Rubin-Carrez C, Deutsch E.
    Invest New Drugs; 2013 Apr 01; 31(2):273-84. PubMed ID: 22810221
    [Abstract] [Full Text] [Related]

  • 13. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Li SH, Lin WC, Huang TL, Chen CH, Chiu TJ, Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, Su YY, Chuang HC, Chien CY.
    Head Neck; 2016 Apr 01; 38 Suppl 1():E844-52. PubMed ID: 25917382
    [Abstract] [Full Text] [Related]

  • 14. Study on the sensitizing effect of SM-1 combined with irradiation on head and neck squamous cell carcinoma.
    Hu T, Liu GT, Wang DD, Xiao YT, Gou WF, Zuo DY, Hou WB, Li YL.
    Int J Radiat Biol; 2024 Apr 01; 100(10):1453-1461. PubMed ID: 39136543
    [Abstract] [Full Text] [Related]

  • 15. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ, Guerra-Librero A, Fernandez-Gil BI, Florido J, García-López S, Martinez-Ruiz L, Mendivil-Perez M, Soto-Mercado V, Acuña-Castroviejo D, Ortega-Arellano H, Carriel V, Diaz-Casado ME, Reiter RJ, Rusanova I, Nieto A, López LC, Escames G.
    J Pineal Res; 2018 Apr 01; 64(3):. PubMed ID: 29247557
    [Abstract] [Full Text] [Related]

  • 16. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH, Chuang HC, Lin YT, Tsai MH, Kao YH, Lin IC, Huang TL, Fang FM, Chien CY.
    Int J Mol Sci; 2021 Mar 17; 22(6):. PubMed ID: 33802643
    [Abstract] [Full Text] [Related]

  • 17. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.
    Matzinger O, Viertl D, Tsoutsou P, Kadi L, Rigotti S, Zanna C, Wiedemann N, Vozenin MC, Vuagniaux G, Bourhis J.
    Radiother Oncol; 2015 Sep 17; 116(3):495-503. PubMed ID: 26096848
    [Abstract] [Full Text] [Related]

  • 18. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 19. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, Morris L, Ganly I, Shiao SL, Powell SN, Chung CH, Scaltriti M, Baselga J.
    Clin Cancer Res; 2016 Apr 15; 22(8):2009-19. PubMed ID: 26589432
    [Abstract] [Full Text] [Related]

  • 20. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
    Macha MA, Rachagani S, Qazi AK, Jahan R, Gupta S, Patel A, Seshacharyulu P, Lin C, Li S, Wang S, Verma V, Kishida S, Kishida M, Nakamura N, Kibe T, Lydiatt WM, Smith RB, Ganti AK, Jones DT, Batra SK, Jain M.
    Oncotarget; 2017 Mar 28; 8(13):20961-20973. PubMed ID: 28423495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.